Clinical trials: PSMA PET/CT
Prostate Cancer (Diagnosis)
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
Prostate cancer is one of the most common malignancies in men. Currently, due to the limited diagnostic accuracy of existing imaging tests, there is a risk of missed diagnosis or unnecessary prostate biopsy.
- Trial name
- NCT07690306
- Where
- 6 sites in United States, China
- Volunteers
- 1,500 people
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancer
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide
PSMA-PET/CT response measurements after LHRH agonist and upfront enzalutamide therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.
- Trial name
- PET-MaN-enza (NCT05539300)
- Testing
- PSMA-PET/CT response evaluation
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- UMC Utrecht
Prostate Cancer, Lymph Node Metastases
Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI
Following curative intended therapy in prostate cancer patients, a high proportion of patients (approx. 25%) relapse with local and/or distant recurrence.
- Trial name
- MAGNIFY (NCT03223064)
- Testing
- Ferumoxtran-10 enhanced MRI; MRI contrast agent, 68Ga PSMA PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
- Trial name
- NCT03471650
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Diagnosis
PSMA PET Scan and mpMRI for Prostate Cancer Detection
Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.
- Trial name
- NCT05820724
- Testing
- PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer (Adenocarcinoma)
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time.
- Trial name
- NCT06655064
- Testing
- None- Observational
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors…
- Trial name
- BASKET PSMA (NCT03453528)
- Testing
- 68Ga-PSMA
- Where
- Italy
- Volunteers
- 1,225 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Trial name
- PROFLu (NCT06460454)
- Testing
- PET scan of 18F-FDG
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
- Trial name
- Solar-Stage (NCT06235151)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 43 sites in United States
- Volunteers
- 439 people
- Sponsor
- Curium US LLC
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET.
- Conditions
- Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- PSMA-dRT (NCT04457245)
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSMA Positive Tumors or Tumor Tissues, Cancer
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms
Study to collect data from PET/CT-PSMA performed in patients with neoplasms expressing PSMA, other than prostate cancer. Objectives The primary objective is to evaluate the diagnostic performance of PET/CT-PSMA in the staging and…
- Trial name
- MORE-PSMA (NCT06835244)
- Testing
- 68Ga-PSMA-11
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer
Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).
In France, prostate cancer is the most common cancer in men over 50 years of age (nearly 50,000 new cases per year) and is the second most common cause of cancer death in men (approximately 9,000 deaths per year).
- Trial name
- PREOP-PSMA (NCT04745871)
- Testing
- PSMA PET/CT
- Where
- France
- Volunteers
- 112 people
- Sponsor
- University Hospital, Brest
Metastatic Clear Cell Renal Cell Carcinoma
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be…
- Trial name
- NCT06428708
- Testing
- [18F] PSMA-1007 PET/CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
PSMA PET/CT, Prostate Cancer
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy
- Conditions
- PSMA PET/CT, Prostate Cancer, MpMRI
- Trial name
- NCT06901492
- Testing
- Prostate biopsy guided by PSMA PET/CT, Prostate biopsy guided by mpMRI/US, Systematic prostate biopsy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04279561
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate Specific Antigen (PSA) levels.
- Trial name
- NCT04794777
- Testing
- Individualised therapy, Standard salvage therapy
- Where
- 5 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Stefan Carlsson
Prostate Cancer
PSMA PET/CT for Prostate Cancer
Prostate cancer is the most frequently occurring male cancer in Belgium. Patients who have been treated for prostate cancer, i.e.
- Trial name
- NGP2 (NCT03573011)
- Testing
- [18F]PSMA-11
- Where
- Belgium
- Volunteers
- 64 people
- Sponsor
- University Hospital, Ghent